Inordinately high levels of serum immunoreactive insulin in monoclonal immunoglobulinemia (on the problem of "big, big insulin")

Srámková, J; Pav, J.; Engelberth, O.

doi:10.2337/diabetes.24.2.214

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the 10 patients treated for 19 13 and 19 months respectively. Seven out of 13 patients ("responders") experienced a long-lasting GH suppression of more than 50% in the multiple sampling profile (Fig.…”

Section: Control Of Gh Axismentioning

confidence: 99%

See 1 more Smart Citation

Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide

Jakóbisiak

Hána²,

Kršek³

et al. 1994

European Journal of Endocrinology

View full text Add to dashboard Cite

Thirteen patients with active acromegaly despite previous surgery were treated with 30 mg lanreotide im twice a month for 9 months. In 10 subjects the treatment continued to 19 months. GH serum levels of all patients decreased significantly from an initial value of 32.0 (29.4) micrograms/l [median (standard error of median)] to 10.0 (3.6) and 19.1 (5.7) after 3 and 9 months of treatment, respectively. In the 10 patients with the treatment longer than one year the decrease in GH was from 46.8 (29.4) micrograms/l to 12.5 (5.0) and 16.1 (5.3) after 13 and 19 months, respectively. IGF-I serum levels decreased significantly from 1193 (73) micrograms/l to 782 (99) and 621 (103) after 3 and 9 months, respectively, and were normalized in 3 patients. In the 10 patients treated for longer than one year, levels decreased significantly from 1318 (74) micrograms/l to 653 (170) and 742 (180) after 13 and 19 months, respectively. IGF BP-3 levels were reduced to the normal range in 6 patients and decreased from 8.7 (1.5) mg/l to 6.4 (0.8) and to 5.4 (1.0) after 3 and 9 months, respectively. In the patients with the 19 months treatment the decrease was from 9.3 (1.6 mg/l to 3.9 (0.9) and 4.8 (0.9) after 13 and 19 months, respectively. The IGF BP-3 to IFG I ratio increased in 7 patients. This elevation significantly correlated with the decrease in bioassayable somatomedin. Prolactin serum levels fell in all patients with increased prolactin secretion.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Section: Control Of Gh Axismentioning

confidence: 99%

“…The index of precision ( ) for the standard curve varied from 0.08 to 0.18 (mean 0.12). IRI was determined by the modified RIA assay techniques of Yalow and Berson as previously described (13). IRMA kits of Immunotech, Marseille France, were used for determination of prolactin and testosterone.…”

Section: Study Protocolmentioning

confidence: 99%

Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide

Jakóbisiak

Hána²,

Kršek³

et al. 1994

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Total amylase activity (a-1, 4-glucan-4-glucanohydrolase, EC 3.2.1.1) was evaluated by using blue starch substrate (Phadebas, Pharmacia, Uppsala) and the isoenzymes of pancreatic (P) and salivary (S) types were separated by ion-exchange chromatography on minicolumns [8]. Serum insulin levels (IRI) were determined as previously described [9]. The influence of glucose or amino acids on the amylase assay was tested…”

Section: Methodsmentioning

confidence: 99%

Serum isoamylase activities during infusions of glucose and amino acids

Škrha

Srámková

Rehák

et al. 1986

Eur J Clin Investigation

View full text Add to dashboard Cite

This investigation was undertaken to examine the influence of intravenously administered glucose and amino acids on serum isoamylase activities. Significantly decreased serum pancreatic isoamylase was observed during administration of 20% glucose and 8% amino acid solutions intravenously for 2 h as compared with physiological saline solution (P less than 0.005). A significant negative correlation was found between mean values of pancreatic isoamylase (P-isoamylase) in serum and glucose in plasma (r = 0.91, P less than 0.01). We propose that glucose may block the flux of pancreatic amylase across the basolateral membrane of the acinar cell into the blood stream. The mechanisms by which amino acids may decrease P-isoamylase activity in serum are not quite clear. Amino acid stimulated release of pancreatic glucagon which has an inhibitory effect on amylase secretion is highly probable.

show abstract

“…were estimated twice in the last 15 min of both clamps by radioimmunoassay 3. Glucose disposal rate was 19.4 and 39.4 k m o l k g -' min-' at low and high insulin infusion rates, respectively, before diazoxide in 1987, and 15.7 and 33.3 k m o l kg-' min-' in 1988 3 weeks after the hyperglycaemic emergency.…”

mentioning

confidence: 99%

Glucose Metabolism in a Patient with Insulinoma Complicated by Hyperosmolar Non‐ketotic State

Škrha

Svačina

et al. 1990

Diabetic Medicine

View full text Add to dashboard Cite

show abstract

Inordinately high levels of serum immunoreactive insulin in monoclonal immunoglobulinemia (on the problem of "big, big insulin")

Cited by 6 publications

References 0 publications

Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide

Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide

Serum isoamylase activities during infusions of glucose and amino acids

Glucose Metabolism in a Patient with Insulinoma Complicated by Hyperosmolar Non‐ketotic State

Contact Info

Product

Resources

About